Our latest newsletter is ready to read in the Members' library. An email copy will be on its way to you soon.
The current issue of The Lancet (09/06/15) contains 2 articles concerned with the results of the ENGAGE-AF trial of Edoxaban, a Factor Xa inhibitor, for use in patients in AF.
- Wednesday 10th June 2015 (09:00-16:30)
- Course summary
This one day course aims to provide knowledge on the diagnosis and management of DVT and PE with an emphasis on a primary care setting. It will also inform on major developments around VTE prevention for patients admitted to hospital and discuss why it is relevant in primary care.
The current issue of the BMJ (9th April 2015) includes a quick resume of the actions to take when a patient presents with a high INR. Although this will be familiar to most of us, it is a good summary for anyone who needs an update.
The makers of a novel antidote that reverses the anticoagulant effects of the factor Xa inhibitors announced that the second part of a phase 3 study testing the agent met its primary end point. The antidote, an intravenous bolus of andexanet alfa (Portola Pharmaceuticals, San Francisco, CA), produced a "rapid reversal" of the anticoagulant effect of apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) in the ANNEXA-A study, according to the company.